Interim Results of a Time and Motion Survey Regarding Subcutaneous Versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
- Resource Type
- Abstract
- Source
- In
Blood 5 November 2020 136 Supplement 1:30-31 - Subject
- Language
- ISSN
- 0006-4971